Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, and the most aggressive subtype, activated B-cell-like (ABC), kills 60% of patients within three years. One important feature of ABC DLBCL is autocrine signaling by the cytokines IL6 and IL10, which is essential for cancer growth. The molecular mechanisms underlying the cytokine signaling pathway remain undefined and will be a focus of this study. In preliminary results, we identified the constitutively activated kinase downstream of the cytokine pathway as JAK1. Cancer cells require JAK1 activity for survival; JAK1 inhibition by RNA interference or the pharmaceutical inhibitor AZD1480 is lethal to cultured ABC DLBCL cells. As a tyrosine kinase, JAK1 regulates gene expression through phosphorylating STAT3 as well as through a surprising non- canonical mechanism, directly targeting the histone protein H3 for tyrosine 41 phosphorylation (H3Y41p). Genome-wide mapping of this modification identified 2,582 JAK1 target genes. Some of these genes that are induced for expression through H3Y41p are independent of STAT3, including the oncogene MYC and important NF-kB genes MYD88 and IRF4. Given that NF-kB activation is a hallmark of ABC DLBCL and causes auto-secretion of the cytokines IL6 or IL10, JAK1 and NF-kB signaling pathways form a positive feedback loop to promote the survival and proliferation of cancer cells. These findings support the hypothesis that JAK1 regulates gene expression via two complementary pathways to promote cancer cell survival and proliferation, and JAK1 downstream target genes are potential candidates for therapeutic intervention in ABC DLBCL. In fact, the Bruton tyrosine kinase (BTK, upstream of IRF4) inhibitor, Ibrutinib, has been effective in ABC DLBCL. Due to drug resistance, however, Ibrutinib only achieves a temporary remission. The proposed research will test the hypothesis that overcoming acquired resistance to Ibrutinib by combined targeted therapies helps further improve outcomes of ABC DLBCL. Specifically, dual interruption of NF-kB and JAK1 by their inhibitors will be conducted in ABC DLBCL xenograft mouse models as well as in primary patient samples. The goals of the proposed research are to establish a conceptual framework for understanding how JAK1 mediates transcription activation through these two distinct (STAT3-mediated or chromatin targeting) mechanisms, to identify novel molecular targets of JAK1, and to develop a new therapeutic strategy for the disease.

Public Health Relevance

Lymphoma is a cancer derived from lymphocytes, a type of white blood cell, with an annual mortality of over 20,000 patients in the United States. This research aims to uncover the oncogenic signaling pathways in order to identify their important cancer genes. Because some of these cancer genes are required for survival and proliferation of cancer cells, they can be considered molecular targets for treatment interruption.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA187299-04
Application #
9488416
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Jhappan, Chamelli
Project Start
2015-06-01
Project End
2020-05-31
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Lu, Li; Zhu, Fen; Zhang, Meili et al. (2018) Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 115:E498-E505
Zhu, Fen; Hwang, Byounghoon; Miyamoto, Shigeki et al. (2017) Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma. Mol Cancer Res 15:348-357
Drennan, Amanda C; Rui, Lixin (2017) HiJAKing the epigenome in leukemia and lymphoma. Leuk Lymphoma 58:2540-2547
Li, Yangguang; Wang, Fangyu; Lu, Li et al. (2017) NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells. Blood Cancer J 7:632
Zheng, M; Turton, K B; Zhu, F et al. (2016) A mix of S and ?S variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture. Oncogenesis 4:e184
Rui, Lixin; Drennan, Amanda C; Ceribelli, Michele et al. (2016) Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 113:E7260-E7267
Li, Y; Bouchlaka, M N; Wolff, J et al. (2016) FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene 35:6223-6234